Amivantamab + Lazertinib vs Osimertinib for Non-Small Cell Lung Cancer
(MARIPOSA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that any toxicities from prior anticancer therapy must have resolved, which might imply a need to stop certain treatments. It's best to discuss your specific medications with the trial team.
Is the combination of Amivantamab and Lazertinib safe for humans?
What makes the drug combination of Amivantamab and Lazertinib unique for non-small cell lung cancer?
The combination of Amivantamab and Lazertinib is unique because it targets both EGFR and MET mutations, which are common resistance mechanisms in non-small cell lung cancer, and has shown effectiveness in patients who have relapsed after treatment with osimertinib, a standard third-generation EGFR inhibitor.12356
What data supports the effectiveness of the drug combination Amivantamab and Lazertinib for non-small cell lung cancer?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with a specific type of advanced lung cancer (NSCLC) that hasn't been treated before and can't be cured with surgery or radiation. Their tumors must have certain genetic changes (Exon 19 deletions or Exon 21 L858R substitution). They need at least one measurable tumor lesion, no active brain metastases, and no history of severe lung disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either amivantamab and lazertinib combination, osimertinib, or lazertinib as first-line treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Amivantamab
- Lazertinib
- Osimertinib
Amivantamab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University